Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVLO Stock Price Chart Interactive Chart >
EVLO Price/Volume Stats
| Current price | $2.22 | 52-week high | $14.77 |
| Prev. close | $2.07 | 52-week low | $1.42 |
| Day low | $2.02 | Volume | 576,600 |
| Day high | $2.32 | Avg. volume | 354,985 |
| 50-day MA | $2.17 | Dividend yield | N/A |
| 200-day MA | $5.23 | Market Cap | 119.13M |
Evelo Biosciences, Inc. (EVLO) Company Bio
Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Latest EVLO News From Around the Web
Below are the latest news stories about Evelo Biosciences Inc that investors may wish to consider to help them evaluate EVLO as an investment opportunity.
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings EstimatesLet us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings. |
Evelo Biosciences begins dosing in phase 2 trial of EDP1815 for eczemaEvelo Biosciences (EVLO) said the first patient was dosed in a phase 2 trial of EDP1815 to treat patients with mild, moderate, and severe atopic dermatitis, also known… |
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic DermatitisCAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis. “We are pleased that dosing has begun in the Phase 2 trial to eval |
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTInvaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. |
Evelo Biosciences, Inc. (EVLO) Upgraded to Buy: Here's What You Should KnowEvelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
EVLO Price Returns
| 1-mo | 4.72% |
| 3-mo | -33.73% |
| 6-mo | -64.59% |
| 1-year | -84.24% |
| 3-year | -75.28% |
| 5-year | N/A |
| YTD | -63.43% |
| 2021 | -49.79% |
| 2020 | 197.78% |
| 2019 | -68.79% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...